<DOC>
	<DOCNO>NCT01315795</DOCNO>
	<brief_summary>An open-label , Phase II clinical study evaluate efficacy safety lanreotide autogel 90mg every 4 week treatment symptomatic polycystic liver disease , include dose escalation month 6 lanreotide autogel 120mg non responder .</brief_summary>
	<brief_title>Lanreotide Autogel Treatment Symptomatic Polycystic Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cysts</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Liver volume ≥ 4 liter ≥ 20 liver cyst Symptomatic patient define least 2 5 follow symptom related mass effect irrespective intensity : Abdominal distention perceive uncomfortable Frequent abdominal pain Early satiety Nausea ( inclusion dyspeptic complaint ) Dyspnea Diagnosed ADPKD ADPLD Male female patient 18 year old Written inform consent Creatinine clearance &lt; 20 ml/min Patient underwent kidney transplant receive variable dos immunosuppressive therapy and/or present sign rejection past year Hormonal replacement therapy Hormonal contraception Pregnant lactate Presenting uncontrolled disease ( ADPKD/ADPLD ) Planned undergo surgery liver study participation Planned undergo surgery KIDNEY study participation ( ADPKD patient ) Patients know allergy somatostatin analogues component Patients receive somatostatin analogue 6 month precede study inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>polycystic liver disease</keyword>
</DOC>